meta|Evidence - COVID-19
click on circles to display study description...
azithromycin (n=56) vs. standard of care (n=55)
randomized controlled trial some concerns about risk of bias
azithromycine plus lopinavir/ritonavir plus hydroxychloroquine
oral AZM 500 mg daily, oral LPV/r 400/100 mg twice daily and oral HCQ 400 mg daily for 5 days
lopinavir/ritonavir plus hydroxychloroquine
oral LPV/r 400/100 mg twice daily and oral HCQ 400 mg daily for 5 days
COVID 19 hospitalized
open label
1 center, Iran
azithromycin (n=2582) vs. standard of care (n=5181)
randomized controlled trial some concerns about risk of bias
azithromycin
azithromycin 500 mg once daily by mouth or intravenously for 10 days or until discharge. 16% received another macrolide
standard of care
COVID 19 hospitalized
open label
176 centres, UK
azithromycin (n=172) vs. standard of care (n=159)
randomized controlled trial some concerns about risk of bias
azithromycin plus hydroxychloroquine
standard care plus hydroxychloroquine at a dose of 400 mg twice daily plus azithromycin at a dose of 500 mg once daily for 7 days
hydroxychloroquine
standard care plus hydroxychloroquine at a dose of 400 mg twice dailyThe use of glucocorticoids, other immunomodulators, antibiotic agents others than macrolides , and antiviral agents was allowed
3 arms: hydroxychloroquine plus azythromycin, hydroxychloroquine monotherapy and standard of care
COVID-19 mild to moderate
open-label
Brazil, 55 sites
Randomization was performed in blocks of six and was stratified according to the use or nonuse of supplemental oxygen at the time of randomization
azithromycin (n=107) vs. standard of care (n=99)
randomized controlled trial some concerns about risk of bias
azithromycin
azithromycin 500 mg/24 h for 7 days
standard of care
3 arms azithromycin, clarithromycin or standard of care
COVID-19 mild to moderate
open-label
1 centre, Egypt
azithromycin (n=214) vs. standard of care (n=183)
randomized controlled trial some concerns about risk of bias
azithromycin plus SoC
azithromycin (500 mg via oral, nasogastric, or intravenous administration once daily for 10 days) plus standard of care including HCQ 400 mg x2 for 10 days
standard of care without macrolide
Soc include HCQ 400 mg x2 for 10 days for all patients
All patients received hydroxychloroquine (400 mg twice daily for 10 days)
COVID-19 severe or critically
patients admitted to hospital with suspected or confirmed COVID-19 and at least one additional severity criteria as follows: use of oxygen supplementation of more than 4 L/min flow; use of high-flow nasal cannula; use of non-invasive mechanical ventilation; or use of invasive mechanical ventilation
open-label
57 centres in Brazil
Several sites enrolling patients in this trial were also participating in the COALITION I trial, another randomised study from our group that tested hydroxychloroquine, with or without azithromycin, in patients with mild to moderate COVID-19.14 Investigators were not allowed totransfer patients between trials, and co-enrolment was also not possible because the trials’ inclusion criteria were mutually exclusive.
powered by vis.js Network